Answers are grounded in this paper and cite their sources.
Small interfering RNA (siRNA) therapy is a promising, highly evolving, and targeted approach for the treatment of cancer that involves silencing the disease-driving genes via the RNA interference pathway. In this process, siRNA molecules are incorporated into the RNA-induced silencing complex to guide the complex toward complementary messenger RNA targets, causing the degradation of such targets and subsequent suppression of protein synthesis. This allows selective silencing of the oncogenes, reactivation of the tumor suppressor pathways, and chemoresistance reversal in various cancer types. siRNA therapeutics are specifically beneficial as they can target “undruggable” genes, such as transcription factors and non-enzymatic proteins, that are often inaccessible to traditional small molecules or biologics. Moreover, they support precision medicine approaches by promising patient-compliant treatment based on the tumor genetic profiles. However, clinical translation of siRNAs into application has various hurdles, such as rapid systemic degradation mediated by nucleases, limited cellular communication, silencing of the off-target genes, and activation of immune responses. Advanced strategies have been developed to overcome these drawbacks, including advanced delivery using lipid nanoparticles, polymer-based carriers, and viral vectors along with chemical modifications such as siRNAs constructed with 2′-O-methylation, 2′-fluoro, and phosphorothioate linkages to improve stability and target specificity. In addition, pH-sensitive and stimuli-responsive systems are being applied to enhance tumor-targeted release. The preclinical models have evolved from traditional 2D cultures to more sophisticated 3D organoids, patient-derived xenografts, and humanized mouse models. Artificial intelligence systems are also helping accelerate siRNA sequence optimization and delivery design. Given the ongoing clinical trials of several candidates such as STP707 and ALN-VSP, siRNAs have become powerful components of future precision oncology.
No takes yet. Share an insight, caveat, or question.
Bavishi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: